Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, A Phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–24.
Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018;29(3):271–80.
European Commission. Community register of medicinal products for human use. Verzenios. 2018. Available at http://ec.europa.eu/health/documents/community-register/html/h1307.htm.
European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2017a. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/10/WC500236155.pdf. Accessed June 2018.
European Medicines Agency. Palbociclib authorisation details. 2016. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003853/human_med_002034.jsp&mid=WC0b01ac058001d124. Accessed June 2018.
European Medicines Agency. Ribociclib authorisation details. 2017. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004213/human_med_002149.jsp&mid=WC0b01ac058001d124#authorisation. Accessed June 2018.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.
Food & Drug Administration. FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer. 2018. Available at https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm598404. Accessed June 2018.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;10;35(32):3638–46.
Goetz MP, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer – results from the preplanned final PFS analysis. Presented at the American Association for Cancer Research Annual Meeting 2018, 14 – 18 April 2018. Chicago, IL, USA. CT040.
Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047–54.
Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–48.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018; [Epub ahead of print].
Ibrance® Summary of Product Characteristics. 2018. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003853/WC500217196.pdf. Accessed June 2018.
Kaufman PA, Toi M, Neven P, Sohn J, Price GL, Lin Y, et al. Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy. Presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting, 01–05 June 2018. Chicago, IL, USA. A1049.
Kisqali® Summary of Product Characteristics. 2018. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004213/WC500233997.pdf. Accessed June 2018.
Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;20;118(4):493–504.
McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, et al. The role of abemaciclib in treatment of advanced breast cancer. Ther Adv Med Oncol. 2018;10:1758835918776925.
NCT02278120. Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7). Available at https://clinicaltrials.gov/ct2/show/NCT02278120?term=nct02278120&rank=1. Accessed June 2018.
NCT02422615. Study of efficacy and safety of LEE011 in men and postmenopausal women with advanced breast cancer. (MONALEESA-3). Available at https://clinicaltrials.gov/ct2/show/NCT02422615?term=MONALEESA-3&rank=1. Accessed June 2018.
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888–94.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: Efficacy and safety updates with longer follow-up across patient subgroups. Presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), 05–09 December 2017. San Antonio, TX, USA. P5-21-03.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018; [Epub ahead of print].
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.
Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, et al. Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic-pharmacodynamic modeling and simulation approach. J Clin Pharmacol. 2017;57(9):1159–73.
Tripathy D, Im S, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15.
Turner N, André F, Cristofanilli M, Verma S, Iwata H, Loi S, et al. Treatment post-progression in women with endocrine-resistant HR+ HER2– advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3. Presented at the San Antonio Breast Cancer Symposium (SABCS). 06–10 December 2016. San Antonio, TX, USA.
Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, Phase III study (PALOMA-3). Oncologist. 2016;21(10):1165–75.
Verma S, O'Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat. 2018; [Epub ahead of print].
Verzenio™ Prescribing Information. 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208855s000lbl.pdf. Access June 2018.
Verzenios® Summary of Product Characteristics. 2018. Available at: https://www.medicines.org.uk/emc/product/9532 Accessed October 2018.